UKOF 2018 | Combination and monotherapies in NSCLC

An influx of novel therapies into the field of non-small cell lung cancer (NSCLC) has allowed healthcare professionals to utilize both combination and monotherapies in clinical practice. Speaking at the UK Oncology Forum (OF) 2018, held in Liverpool, UK, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, explores how both monotherapies and combination therapies have been used with efficacy. He discusses the use of pembrolizumab, nivolumab and atezolizumab based on both PD-L1 expression status and the stage of treatment. Importantly, combinations of immunotherapies and chemotherapies are evaluated in terms of positive Phase III trials, with Dr Greystoke assessing whether this could pave the way for the future of NSLC management.